Best Life Sciences Companies in New South Wales, Australia
The 213 best Life Sciences companies in New South Wales, Australia in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Novotech.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in New South Wales
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Novotech 🦄 Provider of clinical research services across all trial phases and therapeutic areas 72Funding top 25%Fin. health top 26%Product top 26%Innovation top 34% All 10 signals ▾Fundingtop 25% Fin. healthtop 26% Producttop 26% Innovationtop 34% Markettop 36% Techtop 37% Moattop 37% Growthbottom 46% Globalbottom 39% Newsbottom 34% Funding: Raised $255M across 2 rounds · 2 rounds over 13 yrs (0.2/yr) Fin. health: Revenue ~$336M · Revenue +4% YoY rank vs industry peers · Fliar Intelligence Index 72/100 | $255M | 14 mo ago | Acquired | 51 | — | DrupalApple iCloud MailMicrosoft 365+28 | — | 1 partnership |
| 2 | Kazia Therapeutics Developer of small molecules for the treatment of cancer | $86M | 6 mo ago | Public | 9 | — | ZURB FoundationMicrosoft ASP.NETAmazon Web Services+14 | 3 patents Novel functionalized benzopyran compounds for therapeutic drug development | 1 expansion · 1 award |
| 3 | Viralytics Developing oncolytic virotherapy treatments for a range of cancers such as Melanoma, bladder cancer. | $83M | 101 mo ago | Acquired | 6 | — | — | 59 patents Oncolytic virus-based cancer therapies and combination immuno‑stimulatory treatments | — |
| 4 | SpeeDx Provider of qPCR-based molecular diagnostics platform | $78M | 39 mo ago | Series C | 113 | Alison Todd Co-Founder | WordPressMySQLPHP+41 | — | 5 partnerships |
| 5 | Benitec Biopharma Limited Developer of RNAi-based therapies for infectious, ocular, and genetic diseases | $71M | 25 mo ago | Public | 18 | — | BootstrapApache HTTP ServerjQuery+10 | 120 patents Engineered AAV gene‑therapy vectors and OPMD therapeutic reagents for muscle disease treatment | — |
| 6 | Pharmaxis Developer of drugs for inflammatory and fibrotic diseases | $68M | 46 mo ago | Public | 93 | Gary Phillips CEO | — | 145 patents Small-molecule lysyl oxidase and amine oxidase inhibitors for therapeutic use | — |
| 7 | Immutep Developer of immunotherapies for the treatment of cancer and autoimmune diseases | $66M | 59 mo ago | Acquired | 35 | Marc Voigt CEO | WordPressMySQLPHP+12 | — | — |
| 8 | Heart Ware Implantable ventricular assist devices | $55M | 202 mo ago | Late Stage | — | Doug Godshall President & CEO | — | — | — |
| 9 | Inventia Life Science Developer of 3D bio-printers | $50M | 48 mo ago | Series B | 90 | Aidan O'Mahony Co-Founder & CTO | HubSpot CMS HubApple iCloud MailMicrosoft 365+19 | 43 patents 3D bioprinting hardware and processes for fabricating tissue constructs | — |
| 10 | ImmVirX Developer of immunotherapy for cancer treatment | $47M | 36 mo ago | Series B | 16 | Malcolm McColl Co-Founder & CEO | — | — | — |
| 11 | Clinical Genomics Biomarker-based blood tests for early cancer detection | $41M | 96 mo ago | Deadpooled | 50 | Susanne Pedersen Co-Founder & CSO | — | 256 patents Colorectal cancer epigenetic methylation biomarker panels for diagnostic testing | — |
| 12 | Recce Developer of antibiotics for drug-resistant bacteria and cancer treatments | $41M | 12 mo ago | Public | — | James Graham CEO | WordPressMySQLPHP+26 | 8 patents Antimicrobial polymer therapeutics for viral and bacterial infection treatment | 4 partnerships |
| 13 | Actinogen Mdical Developer of therapeutics for the treatment of cognitive impairment | $40M | 54 mo ago | Public | — | Steven Gourlay CEO & Managing Director | WordPressMySQLPHP+18 | — | 1 award |
| 14 | Clarity Pharmaceuticals Developer of drugs to treat cancer | $28M | 10 mo ago | Public | 41 | — | WordPress Block EditorwpBakeryWordPress+24 | 129 patents Targeted radiopharmaceuticals for prostate and neuroendocrine cancer imaging and therapy | — |
| 15 | OncoSil Medical Developer of a medical device for the treatment of pancreatic cancer | $28M | 12 mo ago | Public | 2 | Daniel Kenny Chief Executive Officer | WordPressMySQLPHP+28 | 7 patents Patents concentrated in health & consumer products | 1 partnership |
| 16 | HealthMatch Provider of patient recruitment platform 62Tech top 24%Funding top 38%Growth top 45%AI top 45% All 7 signals ▾Techtop 24% Fundingtop 38% Growthtop 45% AItop 45% Marketbottom 44% Globalbottom 37% Newsbottom 22% Tech: 32 technologies across 7/8 capability areas · Cloud: Amazon Alb, Amazon Cloudfront Funding: Raised $27.5M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 62/100 | $28M | 45 mo ago | Series C | 31 | — | Google Sign-inMUIReact+13 | — | — |
| 17 | Nanosonics Disinfection systems for Ultrasound probe disinfection | $27M | 135 mo ago | Public | 482 | Michael Kavanagh CEO & President | WebflowMicrosoft ASP.NETBootstrap+27 | 6 patents Traceability and hygiene compliance management for reusable medical device reprocessing | — |
| 18 | Star Combo Dietary supplements for improving strength and focus | $25M | 70 mo ago | Public | — | Su Zhang CEO | PHPThinkPHPBootstrap+5 | — | — |
| 19 | EnGeneIC Developer of targeted anti-cancer therapies using nanocell platform technology | $25M | 110 mo ago | Series B | 30 | — | — | — | — |
| 20 | Topelia Developer of antiviral triple therapy for coronavirus infection | $25M | 56 mo ago | Series A | — | David Fox CEO | — | — | — |
| 21 | Medlab Developer of pharmaceuticals, nutraceuticals and biologics for treating chronic diseases | $23M | 53 mo ago | Public | 48 | — | — | — | — |
| 22 | Simavita Provider of urinary incontinence assessment tool | $19M | 65 mo ago | Late Stage | 48 | — | — | — | — |
| 23 | Infensa Developer of peptide drugs for cardiovascular disorders | $16M | 47 mo ago | Series B | 1 | Mark Smythe Chief Executive Officer | — | — | — |
| 24 | Elastagen Company offering solutions for cell growth and tissue repair through their Elastin technology | $15M | 116 mo ago | Acquired | 5 | — | — | — | — |
| 25 | Psylo Developer of psychedelic derived therapeutic for mental illness | $14M | 24 mo ago | Seed | 24 | Josh Ismin Co-Founder & CEO | — | — | — |
| 26 | Genetic Signatures Molecular diagnostic reagents and kits for pathogen detection | $11M | 117 mo ago | Public | — | — | WordPressApple iCloud MailMySQL+26 | 166 patents Isothermal nucleic acid amplification and molecular detection of microbial genetic material | 4 job openings |
| 27 | The Beauty Chef Developer of probiotics for improving gut health | $10M | 79 mo ago | Series A | 25 | Carla Oates Founder & CEO | Cart FunctionalityShopifyBootstrap+47 | — | — |
| 28 | Minomic Non-invasive blood tests for cancer | $8M | 114 mo ago | Series A | 14 | Brad Walsh Founder & CEO | — | — | — |
| 29 | Haemalogix Developer of immunotherapies for blood cancers and autoimmune diseases | $7M | 57 mo ago | Series A | 8 | — | — | 23 patents Therapeutic peptides and antibody-based drugs targeting myeloma antigens. | — |
| 30 | All G Developer of animal-free proteins using precision fermentation for nutrition applications 21Funding top 43%Global top 45%Talent bottom 49%Tech bottom 44% All 5 signals ▾Fundingtop 43% Globaltop 45% Talentbottom 49% Techbottom 44% Marketbottom 25% Funding: Raised $6.6M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Global: Investors from 3 countries beyond Australia rank vs industry peers · Fliar Intelligence Index 21/100 | $7M | 6 mo ago | Series A | — | Jan Pacas Co-Founder & CEO | WordPressMySQLPHP+27 | — | — |
| 31 | Palomar Medical Technologies Lasers and other light-based products, and related disposable items and accessories for use in dermatology… | $4M | 279 mo ago | Acquired | — | Joseph Caruso ex-CEO | — | — | — |
| 32 | TruScreen Cervical cancer screening device | $4M | 110 mo ago | Public | — | — | Cart FunctionalitySquarespace CommerceSquarespace+16 | — | 1 partnership · 1 expansion |
| 33 | Pharmamark Provider of microencapsulation technology for nutraceuticals and bio-active compounds | $4M | 82 mo ago | Series A | — | Guy Drummond Co-Founder & CEO | — | — | — |
| 34 | Cambium Bio Developer of therapeutics for ophthalmology and tissue regeneration | $4M | 4 mo ago | Public | — | Karolis Rosickas CEO | — | — | 1 partnership |
| 35 | Baymatob AI-based health risk analysis tool for healthcare professionals | $3M | 28 mo ago | Series A | 22 | Tara Croft CEO | — | — | — |
| 36 | Evrima Evrima Technologies expedites the clinical trial process by enabling the discovery and registration of active… | $3M | 45 mo ago | Seed | 24 | Charlotte Bradshaw Founder & CEO | HubSpot CMS HubEnvoycore-js+17 | — | — |
| 37 | Beroni Group Developer of cell therapies for treating cancer | $2M | 32 mo ago | Public | 65 | Jacky Zhang CEO | — | — | — |
| 38 | Vectus Biosystems Develops drug discovery platform | $2M | 43 mo ago | Public | — | Karen Duggan Founder & CEO | — | 258 patents Small-molecule therapeutics targeting organ fibrosis (kidney, liver, lung, hypertension). | — |
| 39 | Celosia Therapeutics Developer of therapeutics for neurodegenerative diseases | $2M | 42 mo ago | Seed | 1 | Lars Ittner Co-Founder | WordPress Block EditorWordPressMySQL+13 | 9 patents Protein therapeutics targeting phosphorylated tau and p38γ for neurodegenerative disease treatment | — |
| 40 | Regeneus Cell based therapies with a focus on osteoarthritis and other musculoskeletal disorders, oncology and… | $2M | 93 mo ago | Public | 15 | — | — | 6 patents Adipose-derived cell suspension therapies and related processing technologies | — |
| 41 | Solvanix Provides technology for improving stability and reducing the aggregation of fully human antibodies | $2M | 137 mo ago | Deadpooled | — | Daniel Christ Founder & CSO | — | — | — |
| 42 | Memphasys Developer of the reproductive cell separation technique | $2M | 46 mo ago | Public | 28 | — | — | 26 patents Biomedical electrophoresis and fluid diagnostic devices, including sperm sorting and antioxidant testing. | 1 partnership · 1 expansion |
| 43 | The Best of Moi Internet-first brand offering wellness and nutritional supplements | $850K | 35 mo ago | Seed | 3 | Lu Nan Founder & CEO | — | — | — |
| 44 | Immune System Therapeutics Monoclonal antibodies (MAbs) to treat cancers and autoimmune diseases | $700K | 255 mo ago | Deadpooled | — | Rosanne Dunn Co-Founder | — | 18 patents Therapeutic antibodies and biologics for treating B‑cell mediated immune disorders | — |
| 45 | Andi Provider of wearable device and app for monitoring body vitals parameters | $600K | 51 mo ago | Deadpooled | 4 | — | — | — | — |
| 46 | BioGenesis Provider of chlorella and spirulina based supplement | $600K | 108 mo ago | Seed | — | Colin McGregor Founder | Cart FunctionalityShopifyTailwind CSS+26 | — | 1 launch · 1 award |
| 47 | Neoclinical Enabling patient recruitment through a searchable registry of clinical trials | $466K | 132 mo ago | Seed | 11 | Geoff Denman Co-Founder & CEO | — | — | — |
| 48 | Respiratory Innovations Medical procedures for monitoring breathing functions and guidance | $400K | 116 mo ago | Deadpooled | — | Sean Pollock COO & Co-Founder | — | — | — |
Top 12 Life Sciences companies in New South Wales
#1
Public · Sydney, New South Wales · founded 1994 · 9 employees$85.7Mraised▾
Developer of small molecules for the treatment of cancer. The lead product Paxalisib is a small molecule inhibitor of the PI3K / Akt / mTOR pathway which regulates growth and cell division is used for the treatment of glioblastoma, DIPG, CNS lymphoma, and brain metastases. Another drug VT801 is a small molecule inhibitor of VEGFR3, which helps in the development of new blood vessels and lymphatic vessels in a growing tumour.
- Dec 2025Post IPO$55.3M
- Aug 2025Post IPO$2.1M
- Jan 2023Post IPO$3.1M
- Oct 2020Post IPO$11.8M
#2
Novotech 🦄Acquired · Sydney, New South Wales · founded 2002 · 51 employees$255Mraised▾
Provider of clinical research services across all trial phases and therapeutic areas. It offers services including medical and regulatory consulting, patient recruitment, site selection, early phase trials, clinical operations, project management, site management, biometrics, data management, virtual clinical trials, real-world data analysis, and laboratory services. It also provides specialized services for oncology, pharmacometrics, drug development consulting, GMO solutions, liver disease, infectious diseases, vaccines, and orphan/rare diseases. It focuses on clinical and regulatory strategy to assist biotechnology companies in conducting early-phase clinical trials.
- Mar 2025Seed—
- Jan 2022Conventional Debt$505M
- Jan 2022PE$255M
- Feb 2021PE—
#3
Public · Sydney, New South Wales · founded 2010 · 41 employees$28.1Mraised▾
Developer of drugs to treat cancer. The company utilizes radiopharmaceutical technology for developing targeted therapies. The company has developed drug candidates used for the neuroendocrine tumour, neuroblastoma, colorectal, glioma, and prostate diseases. The company has also developed programs for companion diagnostics in the preclinical stage.
- Jul 2025Post IPO$133.3M
- Mar 2024Post IPO$79M
- Dec 2020Series B$25M
- Jun 2016Grant (prize money)$2.5M
#4
Public · Sydney, New South Wales · founded 2007$40.8Mraised▾
Developer of antibiotics for drug-resistant bacteria and cancer treatments. The company's pipeline includes RECCE 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE 435 (R435) as an orally administered therapy for bacterial infections; and RECCE 529 (R529) for viral infections.
- Jun 2025Post IPO$4.8M
- Apr 2025Post IPO$10.1M
- Sep 2020Post IPO$20.1M
- Oct 2019Post IPO$4.6M
#5
Public · Paddington, New South Wales · founded 2007$3.7Mraised▾
Developer of therapeutics for ophthalmology and tissue regeneration. The company's product line include Elate Ocular to address significant unmet medical needs in the treatment of dry eye disease. In addition, the company's stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
- Jan 2026Post IPO$1.6M
- Dec 2024Post IPO$1.9M
- Sep 2015Grant (prize money)$149.3K
#6
Series A · Waterloo, New South Wales · founded 2020$6.6Mraised▾
Developer of animal-free proteins using precision fermentation for nutrition applications. The company replicates functional proteins found in milk, delivering nutrition with higher purity and lower cost. These next-generation ingredients are applicable to infant, clinical, and animal nutrition, as well as functional foods and skincare. The technology aims to solve for sustainability and open possibilities for health.
- Dec 2025Series A$6.6M
#7
Public · Sydney, New South Wales · founded 2005 · 2 employees$27.8Mraised▾
Developer of a medical device for the treatment of pancreatic cancer. The company's flagship product includes OncoSil which is a brachytherapy device used for the treatment of pancreatic cancer. It is used to deliver beta radiation to the cancerous tissue by causing direct damage to the cancer cell DNA. The device contains proprietary diluent that acts as a carrier to implant the microparticles of radioisotope (phosphorous-32) to the targeted cell.
- May 2025Post IPO$8.7M
- Apr 2022Post IPO$10M
- Feb 2016Post IPO$7.1M
- 2005Post IPO$2M
#8
Public · Sydney, New South Wales · founded 1997 · 18 employees$70.5Mraised▾
Developer of RNAi-based therapies for infectious, ocular, and genetic diseases. The company specializes in genetic medicines that combine gene therapy with DNA-directed RNA interference (ddRNAi) for sustained gene silencing. The company targets chronic and life-threatening conditions like Oculopharyngeal Muscular Dystrophy (OPMD), where its lead candidate BB-301 aims to address moderate dysphagia through a single administration.
- Apr 2024Post IPO$40M
- Sep 2019Post IPO$2.2M
- Feb 2014Post IPO$28.3M
#9
Series C · Sydney, New South Wales · founded 2009 · 113 employees$78Mraised▾
Provider of qPCR-based molecular diagnostics platform. The company's products include multiplexed assays for HSV-1 and -2, VZV, and Syphilis, and detecting the presence of Mycoplasma genitalium as well as antibiotic resistance. The products are based on plexZyme technology where primers amplify target nucleic acid sequences and produce an amplicon.
- Feb 2023Series C$26M
- May 2021Grant (prize money)—
- Sep 2020Grant (prize money)—
- Feb 2020Series B$15M
#10
Seed · Sydney, New South Wales · founded 2021 · 24 employees$14.2Mraised▾
Developer of psychedelic derived therapeutic for mental illness. It provides psychedelics drugs that are improved treatments against selective serotonin reuptake inhibitors (SSRI) medications, allowing patients to recover from severe mental illness like treatment-resistant depression, anxiety, addiction, and others.
- Jun 2024Seed$8M
- Oct 2022Seed$5M
- Oct 2021Seed$1.2M
#11
Series B · New Lambton, New South Wales · founded 2019 · 16 employees$47Mraised▾
Developer of immunotherapy for cancer treatment. It offers immuno-oncology agents based on oncolytic viruses that infect and kill cancer cells and induce systemic anti-tumor immune responses.
- Jun 2023Series B$25M
- May 2021Series B$22M
#12
Public · Sydney, New South Wales · founded 1998 · 93 employees$68.2Mraised▾
Developer of drugs for inflammatory and fibrotic diseases. The product pipeline has mechanism-based inhibitors of amine oxidases which include Pan-LOX and PXS-5505 for Myelofibrosis, Liver, and pancreatic cancer. It also offers LOXL-2 and PXS-5382 for antifibrotic CKD / IPF / NASH, Pan-LOXand PXS-6302 for anti-scarring, PXS-4699 for anti-inflammatory muscular dystrophy, and PXS-5370 for anti-inflammatory multiple indications.
- Aug 2022Post IPO$5M
- Apr 2021Post IPO$3.4M
- Sep 2020Grant (prize money)$733.8K
- Aug 2018Post IPO$17.7M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Australia
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 861 Australia-affiliated papers.
- University College London67
- The University of Queensland63
- The University of Melbourne59
- Agriculture and Food54
- La Trobe University35
- Mutant2→11
- Genome1→7
- Immune system1→5
- Antibody1→4
- Mitochondrion2→4
- Gene5→17
- Immune system2→13
- Antibody1→10
- Messenger RNA1→10
- Mutant1→9
- Agriculture5→19
- Sustainability3→8
- Emerging technologies1→4
- Resistance (ecology)3→6
- Bacteria2→5
Where biotechnology is researched across Australia
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.